Mosunetuzumab is in clinical development for the treatment of patients with relapsed or refractory B-cell follicular lymphoma (FL). FL is a type of slow growing blood cancer that affects white blood cells. In FL, the affected white blood cells start to multiply in an abnormal way and begin to aggregate in certain parts of the body such as the lymph nodes. A recurrence of lymphoma after going into complete remission is known as a relapse. Lymphoma that is unresponsive to therapy it is called refractory lymphoma. The condition can become more difficult to treat if it is relapsed or refractory, as treatment options are limited.
Mosunetuzumab is a medicinal product administered intravenously. It works by binding to proteins called CD3 and CD20 expressed on the surface of B-cells and T-cells. This then reduces the growth and expression of cancer causing CD20 on B-cells. If licensed, mosunetuzumab will offer an additional treatment option for adults with relapsed or refractory B-cell follicular lymphoma (FL).
Drugs
January 2021
Belzutifan for von Hippel-Lindau disease-associated clear cell renal cell carcinoma – first line
Belzutifan is in clinical development for the treatment of von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC). VHL is a hereditary disease that results in the body producing an increased amount of the protein hypoxia inducible factor (HIF) – 2α. This leads to an increased risk of tumours developing in various parts of the body including the kidney. Renal cell carcinoma (RCC) is the most common type of kidney cancer. ccRCC is named as such because when this type of tumour is viewed under a microscope the cells appear clear. Currently patients with VHL disease have limited treatment options which focus on surgically removing tumours once they have developed.